Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.36, Bloomberg Earnings reports. The company had revenue of $28.52 million during the quarter, compared to analysts’ expectations of $26.50 million.

Akebia Therapeutics (NASDAQ AKBA) traded up 1.98% during mid-day trading on Wednesday, reaching $13.89. 776,325 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $14.28 and a 200-day moving average price of $11.72. Akebia Therapeutics has a 12-month low of $7.16 and a 12-month high of $16.54. The stock’s market capitalization is $254.19 million.

AKBA has been the subject of several research reports. JMP Securities upped their target price on shares of Akebia Therapeutics from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 26th. HC Wainwright boosted their price target on shares of Akebia Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, April 27th. Needham & Company LLC reissued a “buy” rating and issued a $18.00 price target (up from $14.00) on shares of Akebia Therapeutics in a research note on Thursday, April 27th. Aegis reissued a “buy” rating on shares of Akebia Therapeutics in a research note on Friday, June 30th. Finally, BidaskClub downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. Akebia Therapeutics has an average rating of “Buy” and a consensus price target of $18.25.

In other news, Director Muneer A. Satter bought 1,034,482 shares of Akebia Therapeutics stock in a transaction that occurred on Wednesday, July 5th. The shares were purchased at an average price of $14.50 per share, with a total value of $14,999,989.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.67% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/akebia-therapeutics-inc-nasdaqakba-issues-quarterly-earnings-results-beats-estimates-by-0-36-eps/1466076.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.